RU2017121191A - Методика размножения гамма-дельта Т-клеток - Google Patents
Методика размножения гамма-дельта Т-клеток Download PDFInfo
- Publication number
- RU2017121191A RU2017121191A RU2017121191A RU2017121191A RU2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- medium
- activator
- preceding paragraphs
- serum
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 23
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000002609 medium Substances 0.000 claims 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 230000000644 propagated effect Effects 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 claims 1
- 239000012894 fetal calf serum Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (21)
1. Способ увеличения популяции γδ Т-клеток, при этом указанный способ включает культивирование выделенных активированных мононуклеарных клеток периферической крови (РВМС) в среде, содержащей трансформирующий фактор роста бета (TGF-β), при условиях, благоприятных для получения эффекторных γδ Т-клеток, имеющих терапевтическую активность в отношении злокачественного заболевания.
2. Способ по п. 1, где среда не содержит фетальной телячьей сыворотки или фетальной бычьей сыворотки.
3. Способ по п. 1 или 2, где среда дополнительно содержит интерлейкин-2.
4. Способ по п. 3, где в среде отсутствуют дополнительные цитокины.
5. Способ по любому из предыдущих пунктов, где среда представляет собой бессывороточную среду или содержит сыворотку АВ человека.
6. Способ по любому из предыдущих пунктов, где активатор для Т-клеток, несущих Vγ9Vδ2, добавляют на начальной стадии процесса.
7. Способ по п. 6, где активатор представляет собой аминобисфосфонат, такой как золедроновая кислота или ее соль.
8. Способ по любому из предыдущих пунктов, где РМВС представляют собой РВМС человека.
9. Способ по п. 8, где РМВС получены от здорового человека.
10. Способ по любому из предыдущих пунктов, где CD19 и/или αβ Т-клетки удаляют из размноженного продукта.
11. Способ увеличения выхода Т-клеток, размноженных in-vitro, при этом указанный способ предусматривает осуществление способа по любому из пп. 1-10.
12. Способ увеличения противоопухолевой эффективности Т-клеток, размноженных in-vitro, при этом указанный способ предусматривает осуществление способа по любому из пп. 1-10.
13. Применение TGF-β для увеличения размножения эффекторных Т-клеток, активных в отношении злокачественного заболевания.
14. Применение TGF-β для увеличения противоопухолевой эффекторной способности Т-клеток.
15. Т-клетки, полученные посредством способа по любому из пп. 1-10.
16. Т-клетки по п. 15 для применения в терапии.
17. Т-клетки по п. 15 для применения в лечении рака.
18. Способ лечения нуждающегося в этом пациента, включающий введение Т-клеток по п. 15.
19. Способ по п. 18, где клетки вводят совместно с активатором.
20. Способ по п. 19, где активатор представляет собой лекарственное средство на основе бисфосфоната или химиотерапевтическое средство.
21. Комбинация цитарабина и γδ Т-клеток для применения в лечении рака.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1421716.0 | 2014-12-05 | ||
| GBGB1421716.0A GB201421716D0 (en) | 2014-12-05 | 2014-12-05 | Cell expansion procedure |
| PCT/GB2015/053713 WO2016087871A1 (en) | 2014-12-05 | 2015-12-04 | Gammadelta t cell expansion procedure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017121191A true RU2017121191A (ru) | 2019-01-10 |
| RU2017121191A3 RU2017121191A3 (ru) | 2019-07-29 |
Family
ID=52425560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121191A RU2017121191A (ru) | 2014-12-05 | 2015-12-04 | Методика размножения гамма-дельта Т-клеток |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10557117B2 (ru) |
| EP (2) | EP3227435B1 (ru) |
| JP (1) | JP6802159B2 (ru) |
| KR (1) | KR102686005B1 (ru) |
| CN (1) | CN107208061A (ru) |
| AU (1) | AU2015356788B2 (ru) |
| CA (1) | CA2969783C (ru) |
| DK (1) | DK3227435T3 (ru) |
| GB (1) | GB201421716D0 (ru) |
| MX (1) | MX2017007214A (ru) |
| RU (1) | RU2017121191A (ru) |
| WO (1) | WO2016087871A1 (ru) |
| ZA (1) | ZA201704499B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| KR102032354B1 (ko) * | 2016-11-11 | 2019-10-16 | 가톨릭대학교 산학협력단 | 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| US20210130777A1 (en) | 2018-07-13 | 2021-05-06 | Kyoto University | Method for producing gamma delta t cells |
| KR20210069665A (ko) * | 2018-09-27 | 2021-06-11 | 포스포감, 인크. | 동종이계 감마/델타-t 세포의 확장 및 사용을 위한 방법 및 조성물 |
| CN109234236A (zh) * | 2018-09-29 | 2019-01-18 | 吉林大学第医院 | 一种嵌合抗原受体γδT细胞的制备方法 |
| CA3118696A1 (en) * | 2018-11-08 | 2020-05-14 | The Uab Research Foundation | Compositions and methods for treating cancer |
| CN110184240B (zh) * | 2019-06-13 | 2020-11-20 | 上海市肺科医院 | 一种高效扩增活化Vγ2Vδ2 T细胞增强其抗结核活性的方法 |
| JPWO2021106832A1 (ru) | 2019-11-25 | 2021-06-03 | ||
| US11999968B2 (en) | 2021-10-22 | 2024-06-04 | Fullhope Biomedical Co., Ltd | Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same |
| KR20230105166A (ko) | 2022-01-03 | 2023-07-11 | 주식회사 이뮤노맥스 | 감마-델타 t 세포의 증식 배양 방법 |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7256498A (en) | 1997-04-25 | 1998-11-24 | Wistar Institute Of Anatomy And Biology, The | Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof |
| PT1028738E (pt) * | 1997-11-05 | 2003-08-29 | Univ Southern California | Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas |
| ES2319942T3 (es) * | 1998-11-04 | 2009-05-14 | Therapure Biopharma Inc. | Procedimientos para la produccion de celulas t tcr gamma delta. |
| US20030157060A1 (en) * | 2000-04-03 | 2003-08-21 | Bell David N | Production of tcr gamma delta t cells |
| FR2836483B1 (fr) | 2002-02-22 | 2006-09-15 | Innate Pharma | Procedes de production de lymphocytes gamma delta t |
| DE60233576D1 (de) | 2002-12-02 | 2009-10-15 | Innate Pharma | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen |
| EP1720567A2 (en) | 2004-02-10 | 2006-11-15 | Innate Pharma | Composition and method for the treatment of carcinoma |
| WO2006006720A1 (ja) * | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤 |
| DK1778836T3 (da) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi |
| AU2006272647A1 (en) | 2005-07-25 | 2007-02-01 | Therimunex Pharmaceuticals, Inc. | Peptidyl diacylglycerides |
| WO2008059052A1 (en) * | 2006-11-17 | 2008-05-22 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| JPWO2008129874A1 (ja) * | 2007-04-13 | 2010-07-22 | 株式会社メディネット | 腫瘍細胞の標的化方法、及びその用途 |
| ITRM20070437A1 (it) | 2007-08-10 | 2009-02-11 | Istituto Naz Per Le Malattie I | Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi |
| US8012466B2 (en) * | 2008-01-31 | 2011-09-06 | University Of Iowa Research Foundation | Immunogenic compositions for activating γδ T cells |
| HUE027084T2 (en) * | 2008-07-01 | 2016-08-29 | Medinet Co Ltd | Method for simultaneous induction of CTL and gamma delta T cells |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| US20140044687A1 (en) * | 2011-03-25 | 2014-02-13 | Txcell | Method for using regulatory t cells in therapy |
| EP2986636B1 (en) | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| CN103436492B (zh) * | 2013-08-02 | 2016-03-02 | 北京赛诺泰生物科技有限公司 | 通过无血清培养扩增活化淋巴细胞的方法 |
| CN103436493B (zh) | 2013-08-29 | 2016-02-03 | 浙江大学 | 雷帕霉素诱导调节性γδT细胞的培养方法 |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
-
2014
- 2014-12-05 GB GBGB1421716.0A patent/GB201421716D0/en not_active Ceased
-
2015
- 2015-12-04 AU AU2015356788A patent/AU2015356788B2/en active Active
- 2015-12-04 WO PCT/GB2015/053713 patent/WO2016087871A1/en active Application Filing
- 2015-12-04 EP EP15819849.9A patent/EP3227435B1/en active Active
- 2015-12-04 DK DK15819849.9T patent/DK3227435T3/da active
- 2015-12-04 MX MX2017007214A patent/MX2017007214A/es unknown
- 2015-12-04 EP EP20152991.4A patent/EP3696263A1/en not_active Withdrawn
- 2015-12-04 KR KR1020177018323A patent/KR102686005B1/ko active IP Right Grant
- 2015-12-04 CA CA2969783A patent/CA2969783C/en active Active
- 2015-12-04 US US15/532,921 patent/US10557117B2/en active Active
- 2015-12-04 JP JP2017529381A patent/JP6802159B2/ja active Active
- 2015-12-04 RU RU2017121191A patent/RU2017121191A/ru not_active Application Discontinuation
- 2015-12-04 CN CN201580072217.6A patent/CN107208061A/zh active Pending
-
2017
- 2017-07-03 ZA ZA2017/04499A patent/ZA201704499B/en unknown
-
2019
- 2019-12-18 US US16/719,650 patent/US11566222B2/en active Active
- 2019-12-18 US US16/719,625 patent/US20200140816A1/en not_active Abandoned
-
2023
- 2023-01-23 US US18/158,146 patent/US20230323298A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3227435B1 (en) | 2020-01-29 |
| WO2016087871A1 (en) | 2016-06-09 |
| DK3227435T3 (da) | 2020-05-04 |
| MX2017007214A (es) | 2018-01-30 |
| EP3227435A1 (en) | 2017-10-11 |
| AU2015356788B2 (en) | 2021-09-30 |
| KR20170084337A (ko) | 2017-07-19 |
| US20200140816A1 (en) | 2020-05-07 |
| US10557117B2 (en) | 2020-02-11 |
| US20230323298A1 (en) | 2023-10-12 |
| AU2015356788A1 (en) | 2017-07-13 |
| RU2017121191A3 (ru) | 2019-07-29 |
| US20200123502A1 (en) | 2020-04-23 |
| EP3696263A1 (en) | 2020-08-19 |
| CA2969783A1 (en) | 2016-06-09 |
| CA2969783C (en) | 2023-08-01 |
| ZA201704499B (en) | 2019-09-25 |
| US11566222B2 (en) | 2023-01-31 |
| GB201421716D0 (en) | 2015-01-21 |
| CN107208061A (zh) | 2017-09-26 |
| JP2017537625A (ja) | 2017-12-21 |
| JP6802159B2 (ja) | 2020-12-16 |
| US20170342381A1 (en) | 2017-11-30 |
| KR102686005B1 (ko) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121191A (ru) | Методика размножения гамма-дельта Т-клеток | |
| JP2017537625A5 (ru) | ||
| MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| AR015926A1 (es) | Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades | |
| WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| ATE308331T1 (de) | Kombinationspräparat enthaltend monozyten- abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen | |
| WO2015154065A1 (en) | Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination | |
| Nouroz et al. | Natural killer cells enhance the immune surveillance of cancer | |
| AU2022228188A1 (en) | Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor | |
| Lou et al. | Retinoic acid inhibits tumor-associated mesenchymal stromal cell transformation in melanoma | |
| Lin et al. | Adoptive transfer of DMSO-induced regulatory T cells exhibits a similar preventive effect compared to an in vivo DMSO treatment for chemical-induced experimental encapsulating peritoneal sclerosis in mice | |
| US20160113966A1 (en) | Composition and methods of culture supernatant of khyg-1 cells | |
| US20170216354A1 (en) | Clinically useful non-antigen pulsed dendritic cells | |
| WO2020185056A3 (ko) | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 | |
| EP1352955A3 (en) | HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula | |
| WO2017142014A1 (ja) | 炎症性疾患を対象とした医薬 | |
| CN103243072A (zh) | CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法 | |
| Krasikov et al. | Analysis of Digital Twin Definition and Its Difference from Simulation Modelling in Practical Application | |
| Molina et al. | A review of IMMUNEPOTENT CRP, a modifier of biological response: efficacy and current practice | |
| CN105198790B (zh) | 促进双阴性t细胞体外增殖的四环化合物 | |
| RU2474421C1 (ru) | Способ профилактики осложнений при лечении больных раком легкого | |
| CN102899289B (zh) | 一种超级cik杀伤细胞的制备方法 | |
| Zhi et al. | Myeloid derived suppressor cells: subsets, expansion, and role in cancer progression | |
| RU2128706C1 (ru) | Иммуномодулирующий препарат "беталейкин" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200316 |